317 results on '"Peck, Carl C."'
Search Results
2. Scientific considerations for global drug development
3. Contributors
4. Disease progress models
5. Clinical Trial Simulation and Quantitative Pharmacology
6. Impact of the Pharmaceutical Sciences on Health Care: A Reflection over the Past 50 Years
7. Chapter 21 - Disease progress models
8. Probability of Success: A Crucial Concept to Inform Decision Making in Pharmaceutical Research and Development
9. Concentration-Controlled Trials: Basic Concepts, Design, and Implementation
10. Opportunities for Integration of Pharmacokinetics, Pharmacodynamics and Toxicokinetics in Rational Drug Development
11. Rationale for the Effective Use of Pharmacokinetics and Pharmacodynamics in Early Drug Development
12. Regulatory Perspectives : Where We Came from, Where Are We Today, Where Are We Headed?
13. Toxic Potential of the Plasticizer Di(2-ethylhexyl) Phthalate in the Context of Its Disposition and Metabolism in Primates and Man
14. Treatment of Tobacco Dependence: Innovative Regulatory Approaches to Reduce Death and Disease: Preface
15. Drug Development: Improving the Process
16. Quantitative clinical pharmacology is transforming drug regulation
17. Simulation of Correlated Continuous and Categorical Variables using a Single Multivariate Distribution
18. Evidence of effectiveness: How much can we extrapolate from existing studies?
19. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis
20. Disease Progress Models
21. Contributors
22. Report of a Workshop on Confirmatory Evidence to Support a Single Clinical Trial As a Basis for New Drug Approval
23. Clinical Trial Simulation and Quantitative Pharmacology
24. Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans
25. Farewell to our Wonderful Friend and Colleague, J. Richard (Dick) Crout (1929–2020)
26. Sir Alasdair Breckenridge 1937–2019. A Celebratory Tribute
27. Contributors
28. Disease Progress Models
29. Clinical Trial Modeling and Simulation—Work in Progress
30. Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development
31. Randomized concentration-controlled trials: Motivations, use, and limitations
32. Hypothesis: A single clinical trial plus causal evidence of effectiveness is sufficient for drug approval
33. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis
34. Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: A conference report
35. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model
36. Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans
37. A pharmacodynamic Markov mixed-effect model for the effect of temazepam on sleep
38. Assessment and reporting of clinical pharmacology information in drug labeling
39. Farewell to our Wonderful Friend and Colleague, J. Richard (Dick) Crout (1929–2020).
40. Dr Marcus M. Reidenberg, Recipient of the 1999 Harry Gold Award
41. A MESSAGE FROM THE PRESIDENT THE CENTENNIAL ASCPT MEETING COME TO SAN ANTONIO, MARCH 18-20, 1999
42. Report on the current status of the use of real‐world data (RWD) and real‐world evidence (RWE) in drug development and regulation
43. Bayesian Approach to Establish Bioequivalence: Why and How?
44. A MESSAGE FROM THE PRESIDENT: THE CENTENNIAL ASCPT MEETING-COME TO SAN ANTONIO, MARCH 18-20, 1999
45. Pharmacodynamics of temazepam in primary insomnia: Assessment of the value of quantitative electroencephalography and saccadic eye movements in predicting improvement of sleep
46. Optimization of Clinical Trial Design Using Simulated Annealing (SA): PI-13
47. Probability of Success: A Crucial Concept to Inform Decision Making in Pharmaceutical Research and Development.
48. Understanding Consequences of Concurrent Therapies
49. Transcutaneous Chemical Collection of Caffeine in Normal Subjects: Relationship to Area Under the Plasma Concentration-Time Curve and Sweat Production
50. Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.